Research powered investment banking
Home
Research
Companies
Find Alpha
Themes
Top Picks
Premium
Transactions
Events
Redeye
At a Glance
Our Culture
Investor Services
Corporate Broking
Certified Adviser
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Members network
Community
sign in
Home
research
Companies
Find Alpha
Themes
Top Picks
Transactions
Events
redeye
About
At a Glance
Our Culture
Investor Services
Corporate Broking
Certified Adviser
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Community
Company overview

Kebni: Q3-numbers in line

Redeye Research Note timeStamp 2020/11/30

Redeye notes that Kebnis´Q3-report is overall in line with what we expected. The business and market related comments in the report are very brief and does not contain any major news. We will probably not make any significant changes to our forecasts or valuation.

Kebni: Actual vs Expected

 

Net sales is lower Y/Y as well as Q/Q following lower sales of maritime antennas to the Israeli customer IAI. As a consequence, EBITDA is now back in the reds. Kebni still has some remaining revenue and cash flow recognition coming from the shipments to Israel. Due to Covid-19 related travel restrictions, the final tests on site have not yet been made. Hopefully this will be resolved in Q4. However, we do not know the amount of these remaining revenues. Also, in this report Kebni has not stated orders received or order backlog.

Total revenues in Q3 were SEK 11m, including SEK 3m of capitalized development costs. Total costs for the period were in line with our estimate and cost items, other than COGS, seem to be basically unchanged Q/Q.

 

Only minor changes in forecasts and valuation
Q3-number were virtually as expected. However. We had hoped for a little more info on the current business pipeline, e.g. order backlog. We will get back with updated estimates and valuation shortly. Probably no big changes at this point.

Henrik Alveskog

Henrik Alveskog

Equity Analyst

Tagged companies
  • Office
  • Mäster Samuelsgatan 42, 10th floor
  • Box 7141, 103 87
  • Stockholm, Sweden
  • info@redeye.se
  • +46 (0)8 545 013 30
  • Services
  • Home
  • Research
  • Transactions
  • Events
  • Redeye
  • Community
  • Members Home
  • Premium
  • Legal
  • Terms and conditions (Swedish)
  • Terms of membership (Swedish)
  • Terms and conditions - Advisory (Swedish)
  • Terms and conditions - Advisory (English)
  • Integrity Policy (Swedish)
  • Disclaimer (Swedish)
  • Governance
  • Follow
  • Twitter
  • Facebook
  • LinkedIn
  • Redeye
  • At a Glance
  • Our Culture
  • Investor Services
  • Corporate Broking
  • Corporate Finance
  • Newsroom
  • The Team
  • Careers
  • FAQ

© All rights reserved. Redeye AB is authorised and regulated by the Swedish Financial Supervisory Authority, Finansinspektionen. 2021

You need to be a Redeye member to access this content

Become a member to:

  • Access all our extensive research on 100+ Nordic Tech and Life Science companies
  • Make smarter investment decisions with the guidance of our experienced analysts
  • Receive exciting offers to participate in IPO’s and other transactions

    By clicking "Sign up" you indicate that you read and agree to our Terms & Conditions

    I already have an account and want to sign in